AGROCHEMICALS
Microbes forming a consortium
an important enabling framework for the next generation of optimised microbial products.
These evolving regulatory structures are positive, but complexity remains. Companies that can navigate multiple regulatory jurisdictions simultaneously, and that have invested in the dossier-building and field trial infrastructure needed to support robust registrations, hold a meaningful advantage.
What the evidence requires
The credibility of microbial agricultural technologies ultimately rests on field performance data. The standards for that data are rising as the sector matures and moves into mainstream agronomy.
The biologicals sector has been ill-served by products that performed in small-scale trials under favourable conditions but failed to replicate results at commercial scale or in variable geographies. The shift towards conventional grower adoption means that performance claims are now being tested under
conditions that allow little margin for inconsistency.
The rigour required to build and sustain credibility in this environment is considerable. It means multi-year, multi-location trial programmes conducted across the range of soil types, climates and agronomic practices relevant to target markets, as well as headto-head comparisons with both the synthetic inputs being complemented or replaced and the competing biological products already in the market. It also means honest communication of where products work well or their performance is more variable, because the credibility of specific claims depends on the perceived credibility of the organisation making them.
This is ultimately an argument for the kind of science-led, dataintensive approach that distinguishes the better companies in this sector. Microbial agricultural technologies have genuine and substantial potential. Realising it requires doing the science properly.
Outlook
The convergence of regulatory pressure on synthetic inputs, grower demand for cost-effective and sustainable alternatives, advances in microbial discovery and formulation, and growing investment in the sector has created a compelling environment for microbial agricultural technologies in the decade ahead.
The companies best positioned to capitalise on this environment are those that have invested consistently in proprietary discovery platforms, that have built the field trial evidence base to support credible performance claims, and that have solved the formulation and supply chain challenges that have historically limited biological product adoption.
The science is advancing. The market is ready. The question for the sector is whether the products can reliably deliver at the scale and consistency that mainstream agriculture demands. Based on what the science is now enabling, there is good reason to think the answer is yes. ●
*- GenExpress, GenePro and SOLVARIX are registered trademarks of BioConsortia
J j
Marcus Meadows-Smith
CEO
BIOCONSORTIA info @ bioconsortia. com www. bioconsortia. com
MAY / JUN 2026 SPECCHEMONLINE. COM
35